September 25, 2020

Goldman Sachs Analyst Rating update on Wuxi Pharmatech (Cayman) Inc.

0
0



Pin It

wx-lMarch 9, 2015 By Joe Willams From Stafford Daily
Equity Analysts at the Goldman Sachs downgrades the rating on Wuxi Pharmatech (Cayman) Inc. (NYSE:WX). The brokerage firm has issued a Neutral rating on the shares. The shares were previously rated Conviction Buy.

Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) has lost 4.86% during the past week and dropped 5.42% in the last 4 weeks. The shares are however, marginally negative as compared to the S&P 500 for the past week with a loss of 3.33%. Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) has underperformed the index by 6.15% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) recorded a 33.01% change in the short interest in the past month. The 3-month %change in short interest stands at 185.77%. A decrease in 1-month short interest eases the pressure off the stock while an increase is a negative overhang. The monthly shorted shares now measure at 0.022 times the total shares outstanding. The companys short ratio is at 3.58. A higher ratio is bearish for the counter while a low ratio eases some negative pressure. The average volume for the past 20 trading days is 668,691 shares. Volume for the last 20 trading sessions stands at 0.96% of the outstanding shares.

Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) was down 7.2% or 2.95 points for the day. The opening trade was executed at $36.61 and the final trade was executed at $38.01. Between these time points, the price failed to break above $38.39 while respecting $33.69 on the lower level. The daily volume was logged at 4,520,034 shares. The counter had ended the earlier session at $40.96. The 52-week high of the stock is recorded as $42.31 while the 52-week low is registered as $29.84. With approx. 70,019,000 shares in outstanding, the company has a market cap of $2,661 million, as per the current valuation.

For more on this story go to: http://stafforddaily.com/goldman-sachs-analyst-rating-update-on-wuxi-pharmatech-cayman-inc-2/359402/

Print Friendly, PDF & Email
About ieyenews

Speak Your Mind

*